Well, I was very excited to go and speak at POSS and to go and talk to many of my colleagues in Saudi Arabia. I think it was a fantastic opportunity to network with all my colleagues there. And it was really great to see so many enthusiastic people there wanting to drive things forward for the people of Saudi Arabia and the Middle East in general. I think where I realise that there is perhaps room for further development is that it would be good to develop a good collaborative network there, like we were seeing good networking and good interactions between the different hospitals...
Well, I was very excited to go and speak at POSS and to go and talk to many of my colleagues in Saudi Arabia. I think it was a fantastic opportunity to network with all my colleagues there. And it was really great to see so many enthusiastic people there wanting to drive things forward for the people of Saudi Arabia and the Middle East in general. I think where I realise that there is perhaps room for further development is that it would be good to develop a good collaborative network there, like we were seeing good networking and good interactions between the different hospitals. And if there can be an improvement in collaboration, then hopefully, in years to come, they could develop a good trials portfolio there. Because I think it is very useful to be able to capture both the real world outcomes for patients in the Middle East but also develop trial programs there because as we all know all these drugs may work in slightly different ways in people of different ethnicities and there may be different toxicities related to that, so it is important to be able to deliver trials across the world to capture the full ethnic profile of everyone to really understand how these drugs work.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
